8-K
filed May 29, 2026, 4:05 PM ET
ticker ACAD
CIK 0001070494
other material
confidence high
sentiment neutral
materiality 0.50
Acadia shareholders approve 5.2M-share increase to 2024 equity plan, re-elect three Class I directors
ACADIA PHARMACEUTICALS INC
- Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 5,209,670.
- Re-elected Class I directors James M. Daly, Edmund P. Harrigan, and Adora Ndu to Board until 2029.
- Advisory vote on executive compensation approved with 98.7% of votes cast in favor.
- Ernst & Young ratified as independent auditor for FY2026 with 157,409,378 votes for.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote: For Against Abstain 157,409,378 3,319,736 76,027
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Election of three Class I directors at the 2026-05-29 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
The following three Class I directors were elected by the votes indicated: For Withheld Broker Non-Votes James M. Daly 146,927,745 3,521,002 10,356,394 Edmund P. Harrigan, M.D. 128,460,130 21,988,617 10,356,394 Adora Ndu, Pharm.D., J.D. 134,540,552 15,908,195 10,356,394
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Advisory approval of named executive officer compensation at the 2026-05-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
the approval, on an advisory basis, of the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote: For Against Abstain Broker Non-Votes 148,265,173 1,911,358 272,216 10,356,394
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
ACADIA PHARMACEUTICALS INC shareholders approved Approval of amendment to the Plan to increase authorized shares by 5,209,670 shares at the 2026-05-29 meeting.
- Proposal
- equity plan
- Outcome
- passed
- Meeting
- 2026-05-29
Exact text from the filing
the approval of an amendment to the Plan to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the Plan by 5,209,670 shares, which was approved by the following vote: For Against Abstain Broker Non-Votes 147,258,860 3,096,136 93,751 10,356,394
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.